LATEST
186,000 Arabic Posts Flagged, Five in Hebrew: The Fight Over Gaza’s Public RecordAs Gaza’s Tents Flood and Claim Young Lives, Israel's Channel 14 Turns Palestinian Suffering into a Water Park JokeSecret UK Arms Files Reveal Wartime Exports and Unanswered Questions Over Israel RestrictionsTO THE NEW Joins SpaceX Super Intelligence Partner Network to Scale AI-Assisted DevelopmentNobel Peace Prize Laureate Urges Israelis to Act Over Gaza Genocide as American Jewish Dissent DeepensTerry Dubrow: “You Can’t Trust Every Company Selling GLP-1 Drugs Online.” So He Founded One.Pia and Joshua Filler Introduce KillerFillers Jump, Break, and Jump/Break Tip Line Developed with TitlistA2C and Andrea Pusateri Bring “Here for the Ride” to Sardinia for a Five-Stage Grand Loop Cycling ChallengeCoatingSolution4U Launches First Commercial PlasticXpert Service at CEPLAA Hospital Bombed, a Population Trapped: Gaza’s Ceasefire of Impunity186,000 Arabic Posts Flagged, Five in Hebrew: The Fight Over Gaza’s Public RecordAs Gaza’s Tents Flood and Claim Young Lives, Israel's Channel 14 Turns Palestinian Suffering into a Water Park JokeSecret UK Arms Files Reveal Wartime Exports and Unanswered Questions Over Israel RestrictionsTO THE NEW Joins SpaceX Super Intelligence Partner Network to Scale AI-Assisted DevelopmentNobel Peace Prize Laureate Urges Israelis to Act Over Gaza Genocide as American Jewish Dissent DeepensTerry Dubrow: “You Can’t Trust Every Company Selling GLP-1 Drugs Online.” So He Founded One.Pia and Joshua Filler Introduce KillerFillers Jump, Break, and Jump/Break Tip Line Developed with TitlistA2C and Andrea Pusateri Bring “Here for the Ride” to Sardinia for a Five-Stage Grand Loop Cycling ChallengeCoatingSolution4U Launches First Commercial PlasticXpert Service at CEPLAA Hospital Bombed, a Population Trapped: Gaza’s Ceasefire of Impunity
Business

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that new preclinical data for ProMIS’ lead candidate for AD, PMN310, will be presented as a virtual short oral poster presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2023) to be held on March 28-April 1, 2023 virtually and in Gothenburg, Sweden.

  Presentation Details:

 

Title: Differentiation of PMN310 from Other Amyloid-Beta-Directed Antibodies: Ability to Selectively Target Toxic Brain Oligomers Despite Competing Monomers and Plaque  

The virtual poster (P0214) will be available during the AD/PD 2023 medical conference starting March 28, 2023 and available on ProMIS’ website.

 

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

 

www.promisneurosciences.com

Related articles

Top